Making Primary Breast Cancer Prevention a Reality

Treating healthy women with tamoxifen can cut breast cancer incidence by 50%, but severe side effects limit its use. At SABS 2024, Per Hall from Karolinska Hospital presented new findings on a tamoxifen metabolite that may offer a safer alternative. In this MEDtalk, he shares his perspective on the data and its implications for primary breast cancer prevention.